Form 10-Q Mersana Therapeutics, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Citi Starts Mersana (MRSN) at Buy
November 15, 2024 4:52 AM ESTCiti analyst Yigal Nochomovitz initiates coverage on Mersana (NASDAQ: MRSN) with a Buy rating and a price target of $5.00.
The analyst comments "
MRSN expects to share initial data from the XMT-1660 (B7-H4 ADC) Ph1 by YE24. We see this readout as a... More
